Fnhlid1
Non-Hodgkins Lymphoma
Biovest InternationalvaccinePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
411 Active assets in the Non-Hodgkins Lymphoma cohort.
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →